Oruka Therapeutics, Inc. (ORKA)
NASDAQ:ORKA
Want to see ORKA full AI Analyst Report?
ORKA Stock Chart & Stats
$68.92
-$0.35(-1.84%)
At close: 4:00 PM EST
$68.92
-$0.35(-1.84%)
Day’s Range― - ―
52-Week Range$10.77 - $91.00
Previous CloseN/A
Volume71.58K
Average Volume (3M)1.28M
Market Cap
$4.36B
Enterprise Value$2.61B
Total Cash (Recent Filing)$388.83M
Total Debt (Recent Filing)$1.81M
Price to Earnings (P/E)―
Beta1.21
Next Earnings
Aug 17, 2026EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding60,312,100
10 Day Avg. Volume1,264,458
30 Day Avg. Volume1,278,814
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)2.93
Price to Sales (P/S)0.00
P/FCF Ratio-15.64
Enterprise Value/Market Cap0.60
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-36.72K
Enterprise Value/Ebitda-22.44
Forecast
1Y Price Target
$148.20Price Target Upside115.03% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering12
EPS Forecast (FY)-2.14
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strong Balance Sheet With Low Leverage And Sizable CashOruka’s extremely low leverage and large equity base materially reduce refinancing risk and preserve strategic optionality. Combined with the recent equity raise and ~ $496M cash estimate, the company can fund clinical programs and partner negotiations over multiple quarters, supporting R&D continuity.
Robust Phase 2a Efficacy And Favorable Safety In PsoriasisHigh complete-clearance rates and a placebo-like safety profile materially de-risk clinical development in psoriasis. Durable efficacy and tolerability strengthen the therapy’s commercial prospects, increase partner interest, and improve the odds of progressing through later-stage trials toward approval.
Long-acting Pharmacology Supports Potential Once‑yearly DosingSustained PK/PD for a year after a single dose could create a structural competitive edge versus more frequent biologics. Once‑yearly dosing enhances adherence, reduces administration burden, and can be a durable differentiator with payors and prescribers, supporting premium positioning and partnership value.
Bears Say
Pre-revenue Model With Widening Net LossesThe company generates no product revenue and reported expanding net losses, reflecting program spending. This structural dependence on clinical success and external financing increases dilution and execution risk, making sustainability contingent on trial outcomes and access to capital.
Sustained Heavy Cash Burn And Ongoing Funding NeedsHigh and rising cash outflows mean the company will need to manage runway actively despite recent proceeds. Continued development and enrollment costs will consume cash, potentially necessitating further capital raises that can dilute shareholders and force prioritization or delay of certain programs.
IL‑23 License Imposes Dosing And Combination RestrictionsContractual limits on dosing and combination use for ORKA‑001 in IBD constrain the company’s ability to pursue that indication and complicate partnering or M&A strategies. These structural restrictions could narrow near-term addressable markets and delay commercialization opportunities for certain indications.
Oruka Therapeutics News
ORKA FAQ
What was Oruka Therapeutics, Inc.’s price range in the past 12 months?
Oruka Therapeutics, Inc. lowest stock price was $10.77 and its highest was $91.00 in the past 12 months.
What is Oruka Therapeutics, Inc.’s market cap?
Oruka Therapeutics, Inc.’s market cap is $4.36B.
When is Oruka Therapeutics, Inc.’s upcoming earnings report date?
Oruka Therapeutics, Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 57 days.
How were Oruka Therapeutics, Inc.’s earnings last quarter?
Oruka Therapeutics, Inc. released its earnings results on May 13, 2026. The company reported -$0.48 earnings per share for the quarter, beating the consensus estimate of -$0.547 by $0.067.
Is Oruka Therapeutics, Inc. overvalued?
According to Wall Street analysts Oruka Therapeutics, Inc.’s price is currently Undervalued.
Does Oruka Therapeutics, Inc. pay dividends?
Oruka Therapeutics, Inc. pays a Notavailable dividend of $19.356 which represents an annual dividend yield of N/A. See more information on Oruka Therapeutics, Inc. dividends here
What is Oruka Therapeutics, Inc.’s EPS estimate?
Oruka Therapeutics, Inc.’s EPS estimate is -0.51.
How many shares outstanding does Oruka Therapeutics, Inc. have?
Oruka Therapeutics, Inc. has 60,312,100 shares outstanding.
What happened to Oruka Therapeutics, Inc.’s price movement after its last earnings report?
Oruka Therapeutics, Inc. reported an EPS of -$0.48 in its last earnings report, beating expectations of -$0.547. Following the earnings report the stock price went up 1.14%.
Which hedge fund is a major shareholder of Oruka Therapeutics, Inc.?
Currently, no hedge funds are holding shares in ORKA
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Oruka Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$148.20 (115.03% Upside)
$148.20 (115.03% Upside)
Blogger Sentiment
Bullish
ORKA Sentiment 70%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $325.9K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.6%
Last 30 Days ▼ 1.6%
Last 30 Days ▼ 1.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
503.83%
12-Months-Change
Fundamentals
Return on Equity
-25.99%
Trailing 12-Months
Asset Growth
33.77%
Trailing 12-Months
Company Description
Oruka Therapeutics, Inc.
Oruka Therapeutics, Inc. functions as a biotechnology firm primarily dedicated to creating groundbreaking monoclonal antibody therapies. These treatments are designed to address Psoriasis (PsO) along with various other inflammatory and immunological (I&I) conditions. Its current development portfolio includes ORKA-001 and ORKA-002. The company's main operations are based in Menlo Park, CA.
ORKA Stock 12 Month Forecast
Average Price Target
$148.20
▲(115.03% Upside)
Technical Analysis
Verastem
―
AnaptysBio
―
Compass Therapeutics
―
Olema Pharmaceuticals
―
Bicara Therapeutics Inc.
―
Ownership Overview
8.27% Insiders
15.45% Mutual Funds
48.75% Other Institutional Investors
16.21% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---